Tag: ALK
Broad Molecular Testing in Lung Cancer: The Struggle to Translate Recommendations...
By Kara Nyberg, PhD
Posted: June 24, 2020
Over the past decade, lung cancer has emerged as a shining example of how precision medicine can dramatically...
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
By Kara Nyberg, PhD
Posted: June 24, 2020
An exploratory analysis of circulating free DNA (cfDNA) shows that lorlatinib confers potent antitumor activity in pretreated patients...
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD
Posted: April 16, 2020
After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life...
Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies
By Robert C. Doebele, MD, PhD
Posted: December 11, 2019
Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a...
